These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18502399)

  • 1. Intraocular microinjections repair experimental Parkinson's disease.
    Willis GL
    Brain Res; 2008 Jun; 1217():119-31. PubMed ID: 18502399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL
    Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2004 Nov; 79(3):413-29. PubMed ID: 15582013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
    Willis GL
    Rev Neurosci; 2008; 19(4-5):245-316. PubMed ID: 19145986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.
    Willis GL
    Drug News Perspect; 2005 Sep; 18(7):437-44. PubMed ID: 16362083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease.
    Willis GL; Moore C; Armstrong SM
    Rev Neurosci; 2012 Mar; 23(2):199-226. PubMed ID: 22499678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of intravitreal cholinergic drugs on motor control.
    Willis GL; Freelance CB
    Behav Brain Res; 2018 Feb; 339():232-238. PubMed ID: 29180132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between dopamine and melatonin organize circadian rhythmicity in the retina of the green iguana.
    Bartell PA; Miranda-Anaya M; McIvor W; Menaker M
    J Biol Rhythms; 2007 Dec; 22(6):515-23. PubMed ID: 18057326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
    Glavan G
    Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    van Vliet SA; Vanwersch RA; Jongsma MJ; Olivier B; Philippens IH
    Eur Neuropsychopharmacol; 2008 May; 18(5):383-9. PubMed ID: 18222654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Luthra PM; Barodia SK; Raghubir R
    J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine stimulation via infusion in the lateral ventricle.
    Biagioni F; Busceti CL; Molinaro G; Battaglia G; Giorgi FS; Ruggieri S; Fornai F
    Ann N Y Acad Sci; 2006 Aug; 1074():337-43. PubMed ID: 17105930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.